Highlights Alector, Inc.

Equities

ALEC

US0144421072

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-09 EDT			5-day change	1st Jan Change
5.2 ^USD	+0.19%		-2.62%	-34.84%

05-08	Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024	CI
05-08	Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024	05-08	CI
Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Alector, Inc. Provides Revenue Guidance for the Year Ending 2024	02-27	CI
Alector, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27	CI
Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer?S Disease	02-08	CI
Alector, GSK Say FDA Grants Breakthrough Therapy Label For Frontotemporal Dementia Treatment	02-07	MT
GSK: breakthrough therapy status in dementia	02-07	CF
Alector, GSK Get FDA Breakthrough Designation for Latozinemab	02-07	DJ
Alector, Inc. Announces the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation to Latozinemab	02-07	CI
Alector, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023	11-07	CI
Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)	23-10-27	CI
Alector, Inc. Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002	23-09-07	CI
Alector, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
ALECTOR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-04	AQ
Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Alector, Inc. Provides Revenue Guidance for the Year 2023	23-05-04	CI
ALECTOR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-02-28	AQ
Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alector, Inc.

Equities

ALEC

US0144421072

Highlights

Filters